We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$4.22B
AUM Growth
+$2.7B
Cap. Flow
+$3.76B
Cap. Flow %
89.24%
Top 10 Hldgs %
40.53%
Holding
623
New
593
Increased
5
Reduced
1
Closed
3

Sector Composition

Rank Sector Weight
1 Financials 22.21%
2 Healthcare 21.36%
3 Technology 18.59%
4 Industrials 5.57%
5 Real Estate 5.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ORIA
251
DELISTED
Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
$2.41M 0.06%
+235,390
New +$2.39M
PEGR
252
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
$2.41M 0.06%
+236,311
New +$2.4M
KNSW
253
DELISTED
KnightSwan Acquisition Corporation
KNSW
$2.41M 0.06%
+231,686
New +$2.39M
PNST
254
DELISTED
Pinstripes Holdings, Inc.
PNST
$2.41M 0.06%
+231,686
New +$2.39M
KVSC
255
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
$2.41M 0.06%
+237,220
New +$2.39M
TGVC
256
DELISTED
TG Venture Acquisition Corp. Class A Common Stock
TGVC
$2.4M 0.06%
+231,686
New +$2.38M
CSLM
257
DELISTED
CSLM Acquisition Corp. Class A Ordinary Share
CSLM
$2.4M 0.06%
+231,686
New +$2.38M
BIIB icon
258
Biogen
BIIB
$30.5B
$2.39M 0.06%
+8,610
New +$2.38M
ASBP
259
Aspire Biopharma
ASBP
$9.14M
$2.38M 0.06%
+190
New +$2.38M
RARE icon
260
Ultragenyx Pharmaceutical
RARE
$2.55B
$2.38M 0.06%
+59,276
New +$2.54M
EONR
261
EON Resources
EONR
$23.7M
$2.38M 0.06%
+227,558
New +$2.36M
FLD
262
Fold Holdings
FLD
$25.2M
$2.37M 0.06%
+231,686
New +$2.35M
FGMC
263
DELISTED
FG Merger Corp. Common Stock
FGMC
$2.37M 0.06%
+227,558
New +$2.35M
IMCR icon
264
Immunocore
IMCR
$1.75B
$2.37M 0.06%
+47,865
New +$2.69M
IGTA
265
DELISTED
Inception Growth Acquisition Limited Common Stock
IGTA
$2.36M 0.06%
+231,686
New +$2.37M
ZTO icon
266
ZTO Express
ZTO
$18.3B
$2.36M 0.06%
+82,358
New +$2.25M
PSPC
267
DELISTED
Post Holdings Partnering Corporation
PSPC
$2.34M 0.06%
+231,686
New +$2.33M
ALCE
268
DELISTED
Alternus Clean Energy Inc
ALCE
$2.34M 0.06%
+9,102
New +$2.32M
KNSA icon
269
Kiniksa Pharmaceuticals
KNSA
$5.97B
$2.33M 0.06%
+216,210
New +$2.85M
MTAL
270
DELISTED
Metals Acquisition
MTAL
$2.33M 0.06%
+227,558
New +$2.3M
KPTI icon
271
Karyopharm Therapeutics
KPTI
$44.2M
$2.31M 0.05%
+39,587
New +$1.95M
BSX icon
272
Boston Scientific
BSX
$71.4B
$2.3M 0.05%
+46,008
New +$2.17M
INSP icon
273
Inspire Medical Systems
INSP
$1.7B
$2.29M 0.05%
+9,765
New +$2.47M
XENE icon
274
Xenon Pharmaceuticals
XENE
$6.24B
$2.27M 0.05%
+63,391
New +$2.34M
CMG icon
275
Chipotle Mexican Grill
CMG
$42.7B
$2.24M 0.05%
+65,600
New +$2.06M

Similar funds

UBS O'Connor's Q1 2023 Portfolio in Review

As of Q1 2023, UBS O'Connor held 623 positions worth $4.22B, up 177% from $1.52B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

UBS O'Connor deployed $3.76B of net new capital in Q1 2023, opening 593 new positions and adding to 5 existing holdings. Its largest new stake was Oak Street Health, Inc.: 6,537,297 shares worth $25.3M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, up from 14% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Activision Blizzard, an estimated $196M trimmed.

  • UBS O'Connor's largest Q1 2023 buy was Oak Street Health, Inc.: 6,537,297 shares worth $25.3M.
  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, an estimated $189M increase.
  • UBS O'Connor's biggest Q1 2023 reduction was Activision Blizzard, cutting an estimated $196M.
  • UBS O'Connor fully exited Signify Health, Inc. in Q1 2023, selling an estimated $161M.
  • UBS O'Connor's ten largest holdings make up 41% of its $4.22B portfolio in Q1 2023.
  • UBS O'Connor opened 593 new positions and closed 3 in Q1 2023.
  • UBS O'Connor's portfolio value rose 177% quarter-over-quarter to $4.22B.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.